Emmanuel Morelon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Emmanuel Morelon has a total of 180 co-authors. Here are the top co-authors by number of shared publications:
- Olivier Thaunat
CIRI, Centre International de Recherche en Infectiologie, Université de Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon
11 shared publications Lionel Badet
Université de Lyon, 92, rue Pasteur, CS 30122, 69361 Lyon Cedex 07, France; Service d'urologie et de transplantation, Hôpital Édouard-Herriot, Hospices civils de Lyon, 5, place d'Arsonval, 69003 Lyon, France
8 shared publications- Palmina Petruzzo
Department of Transplantation, Hôpital Edouard Herriot, HCL, Lyon, France
5 shared publications - Jean Kanitakis
Department of Dermatology, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France
4 shared publications Cécile Chauvet
3 shared publications- Emmanuelle Papuchon
ITUN and Inserm U1064, Nantes University, CHU Nantes, Nantes, France.
3 shared publications
Latest Publications
- 19 November 2025
- Published by Elsevier in The French Journal of Urology
- Vol. 35 (11) , 102940
Allograft nephrectomy: Indications and surgical techniques. Association Française d’Urologie and Société Francophone de Transplantation guidelines
- 19 November 2025
- Published by Elsevier in The French Journal of Urology
- Vol. 35 (11) , 102940
Allograft nephrectomy: Indications and surgical techniques. Association Française d’Urologie and Société Francophone de Transplantation guidelines
- 24 February 2023
- Published by Springer Nature
- p. 239-245
Upper Extremity Allotransplantation: Our Long-Term Experience in Lyon
- 24 February 2023
- Published by Springer Nature
- p. 239-245
Upper Extremity Allotransplantation: Our Long-Term Experience in Lyon
- 24 February 2023
- Published by Springer Nature
- p. 67-72
Facial Allotransplantation: Outcomes and Results of the Amiens/Lyon Team
- 24 February 2023
- Published by Springer Nature
- p. 67-72
Facial Allotransplantation: Outcomes and Results of the Amiens/Lyon Team
- 11 January 2019
- Published by Frontiers Media SA in Transplant International
- Vol. 32 (7) , 693-701
Infections after upper extremity allotransplantation: a worldwide population cohort study, 1998‐2017
Risk‐to‐benefit analysis of upper extremity allotransplantation (UEA) warrants a careful assessment of immunosuppression‐related complications. This first systematic report of infectious complications after UEA aimed to compare incidence and pattern of infections to that observed after kidney transplantation (KT). We conducted a matched cohort study among UEA and KT recipients from the International Registry on Hand and Composite Tissue Transplantation and the French transplant database DIVAT. All UEA recipients between 1998 and 2016 were matched with KT recipients (1:5) regarding age, sex, CMV serostatus and induction treatment. Infections were analyzed at three posttransplant periods (early: 0‐6 months, intermediate: 7‐12 months, late: >12 months). Sixty‐one UEA recipients and 305 KT recipients were included. Incidence of infection was higher after UEA than after KT during the early period (3.27 vs 1.95 per 1000 transplant‐days, p=0.01), but not statistically different during the intermediate (0.61 vs 0.45/1000, p=0.5) nor the late period (0.15 vs 0.21/1000, p=0.11). The distribution of infectious syndromes was significantly different, with mucocutaneous infections predominating after UEA, urinary tract infections and pneumonia predominating after KT. Incidence of infection is high during the first 6 months after UEA. After 1 year, the burden of infections is low, with favorable patterns.
- 11 January 2019
- Published by Frontiers Media SA in Transplant International
- Vol. 32 (7) , 693-701
Infections after upper extremity allotransplantation: a worldwide population cohort study, 1998‐2017
Risk‐to‐benefit analysis of upper extremity allotransplantation (UEA) warrants a careful assessment of immunosuppression‐related complications. This first systematic report of infectious complications after UEA aimed to compare incidence and pattern of infections to that observed after kidney transplantation (KT). We conducted a matched cohort study among UEA and KT recipients from the International Registry on Hand and Composite Tissue Transplantation and the French transplant database DIVAT. All UEA recipients between 1998 and 2016 were matched with KT recipients (1:5) regarding age, sex, CMV serostatus and induction treatment. Infections were analyzed at three posttransplant periods (early: 0‐6 months, intermediate: 7‐12 months, late: >12 months). Sixty‐one UEA recipients and 305 KT recipients were included. Incidence of infection was higher after UEA than after KT during the early period (3.27 vs 1.95 per 1000 transplant‐days, p=0.01), but not statistically different during the intermediate (0.61 vs 0.45/1000, p=0.5) nor the late period (0.15 vs 0.21/1000, p=0.11). The distribution of infectious syndromes was significantly different, with mucocutaneous infections predominating after UEA, urinary tract infections and pneumonia predominating after KT. Incidence of infection is high during the first 6 months after UEA. After 1 year, the burden of infections is low, with favorable patterns.
- Open Access
- 1 May 2018
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 33 (suppl_1) , i281
FP697ACTIVABILITY OF CIRCULATING TFH17 PREDICTS HUMORAL RESPONSE TO THYMUS-DEPENDENT ANTIGENS
INTRODUCTION AND AIMS: Despite therapeutic immunosuppression, a significant proportion of transplanted patients develop donor-specific antibodies (DSA), which are currently recognized as the first cause of allograft failure. Generation of antibodies against protein antigens (including donor HLA) results from a thymus-dependent (TD) humoral response, which means that B cells need to receive a co-stimulation signal from activated follicular helper T cells (Tfh) to differentiate into plasmacells.
- 1 May 2018
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 33 (suppl_1) , i281
Open AccessFP697ACTIVABILITY OF CIRCULATING TFH17 PREDICTS HUMORAL RESPONSE TO THYMUS-DEPENDENT ANTIGENS
INTRODUCTION AND AIMS: Despite therapeutic immunosuppression, a significant proportion of transplanted patients develop donor-specific antibodies (DSA), which are currently recognized as the first cause of allograft failure. Generation of antibodies against protein antigens (including donor HLA) results from a thymus-dependent (TD) humoral response, which means that B cells need to receive a co-stimulation signal from activated follicular helper T cells (Tfh) to differentiate into plasmacells.
- 1 April 2018
- Published by JLE in Nephrologie & Therapeutique
- Vol. 14, S23-S30
Stratégie de transplantation chez les patients diabétiques de type 1
Beta cell replacement by pancreas or Langerhans islets transplantation is the only way to restore glucose homeostasis in type 1 diabetic patients. The counterpart is the need for long-term immunosuppression. These transplantations are therefore mainly indicated for patients candidates for kidney transplantation and for patients with poor quality of life due to unstable diabetes with life-threatening hypoglycemic events. Both beta cell replacement techniques have different benefits and risks and should be adapted to each type 1 diabetic patient. The transplant strategy must be personalized according to parameters assessed in the pre-transplant period, validated by a multidisciplinary team and reassessed regularly until transplantation.
- 1 April 2018
- Published by JLE in Nephrologie & Therapeutique
- Vol. 14, S23-S30
Stratégie de transplantation chez les patients diabétiques de type 1
Beta cell replacement by pancreas or Langerhans islets transplantation is the only way to restore glucose homeostasis in type 1 diabetic patients. The counterpart is the need for long-term immunosuppression. These transplantations are therefore mainly indicated for patients candidates for kidney transplantation and for patients with poor quality of life due to unstable diabetes with life-threatening hypoglycemic events. Both beta cell replacement techniques have different benefits and risks and should be adapted to each type 1 diabetic patient. The transplant strategy must be personalized according to parameters assessed in the pre-transplant period, validated by a multidisciplinary team and reassessed regularly until transplantation.
- Open Access
- 8 January 2018
- Published by Springer Nature in BMC Nephrology
- Vol. 19 (1) , 3
Uncontrolled donation after circulatory death: comparison of two kidney preservation protocols on graft outcomes
Kidney transplantation following uncontrolled donation after circulatory death (uDCD) presents a high risk of delayed graft function due to prolonged warm ischemia time. In order to minimise the effects of ischemia/reperfusion injury during warm ischemia, normothermic recirculation recently replaced in situ perfusion prior to implantation in several institutions. The aim of this study was to compare these preservation methods on kidney graft outcomes. The primary endpoint was the one-year measured graft filtration rate (mGFR). We collected retrospective data from 64 consecutive uDCD recipients transplanted over a seven-year period in a single centre. Thirty-two grafts were preserved by in situ perfusion and 32 by normothermic recirculation. The mean ± SD mGFR at 1 year post-transplantation was 43.0 ± 12.8 mL/min/1.73 m2 in the in situ perfusion group and 53.2 ± 12.8 mL/min/1.73 m2 in the normothermic recirculation group (p = 0.01). Estimated GFR levels were significantly higher in the normothermic recirculation group at 12 months (p = 0.01) and 24 months (p = 0.03) of follow-up. We did not find any difference between groups regarding patient and graft survival, delayed graft function, graft rejection, or interstitial fibrosis. Function of grafts preserved by normothermic recirculation was better at 1 year and the results suggest that this persists at 2 years, although no difference was found in short-term outcomes. Despite the retrospective design, this study provides an additional argument in favour of normothermic recirculation.
- 8 January 2018
- Published by Springer Nature in BMC Nephrology
- Vol. 19 (1) , 3
Open AccessUncontrolled donation after circulatory death: comparison of two kidney preservation protocols on graft outcomes
Kidney transplantation following uncontrolled donation after circulatory death (uDCD) presents a high risk of delayed graft function due to prolonged warm ischemia time. In order to minimise the effects of ischemia/reperfusion injury during warm ischemia, normothermic recirculation recently replaced in situ perfusion prior to implantation in several institutions. The aim of this study was to compare these preservation methods on kidney graft outcomes. The primary endpoint was the one-year measured graft filtration rate (mGFR). We collected retrospective data from 64 consecutive uDCD recipients transplanted over a seven-year period in a single centre. Thirty-two grafts were preserved by in situ perfusion and 32 by normothermic recirculation. The mean ± SD mGFR at 1 year post-transplantation was 43.0 ± 12.8 mL/min/1.73 m2 in the in situ perfusion group and 53.2 ± 12.8 mL/min/1.73 m2 in the normothermic recirculation group (p = 0.01). Estimated GFR levels were significantly higher in the normothermic recirculation group at 12 months (p = 0.01) and 24 months (p = 0.03) of follow-up. We did not find any difference between groups regarding patient and graft survival, delayed graft function, graft rejection, or interstitial fibrosis. Function of grafts preserved by normothermic recirculation was better at 1 year and the results suggest that this persists at 2 years, although no difference was found in short-term outcomes. Despite the retrospective design, this study provides an additional argument in favour of normothermic recirculation.
- 20 November 2017
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 128 (1) , 219-232
Endothelial chimerism and vascular sequestration protect pancreatic islet grafts from antibody-mediated rejection
Humoral rejection is the most common cause of solid organ transplant failure. Here, we evaluated a cohort of 49 patients who were successfully grafted with allogenic islets and determined that the appearance of donor-specific anti-HLA antibodies (DSAs) did not accelerate the rate of islet graft attrition, suggesting resistance to humoral rejection. Murine DSAs bound to allogeneic targets expressed by islet cells and induced their destruction in vitro; however, passive transfer of the same DSAs did not affect islet graft survival in murine models. Live imaging revealed that DSAs were sequestrated in the circulation of the recipients and failed to reach the endocrine cells of grafted islets. We used murine heart transplantation models to confirm that endothelial cells were the only accessible targets for DSAs, which induced the development of typical microvascular lesions in allogeneic transplants. In contrast, the vasculature of DSA-exposed allogeneic islet grafts was devoid of lesions because sprouting of recipient capillaries reestablished blood flow in grafted islets. Thus, we conclude that endothelial chimerism combined with vascular sequestration of DSAs protects islet grafts from humoral rejection. The reduced immunoglobulin concentrations in the interstitial tissue, confirmed in patients, may have important implications for biotherapies such as vaccines and monoclonal antibodies.
- 20 November 2017
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 128 (1) , 219-232
Endothelial chimerism and vascular sequestration protect pancreatic islet grafts from antibody-mediated rejection
Humoral rejection is the most common cause of solid organ transplant failure. Here, we evaluated a cohort of 49 patients who were successfully grafted with allogenic islets and determined that the appearance of donor-specific anti-HLA antibodies (DSAs) did not accelerate the rate of islet graft attrition, suggesting resistance to humoral rejection. Murine DSAs bound to allogeneic targets expressed by islet cells and induced their destruction in vitro; however, passive transfer of the same DSAs did not affect islet graft survival in murine models. Live imaging revealed that DSAs were sequestrated in the circulation of the recipients and failed to reach the endocrine cells of grafted islets. We used murine heart transplantation models to confirm that endothelial cells were the only accessible targets for DSAs, which induced the development of typical microvascular lesions in allogeneic transplants. In contrast, the vasculature of DSA-exposed allogeneic islet grafts was devoid of lesions because sprouting of recipient capillaries reestablished blood flow in grafted islets. Thus, we conclude that endothelial chimerism combined with vascular sequestration of DSAs protects islet grafts from humoral rejection. The reduced immunoglobulin concentrations in the interstitial tissue, confirmed in patients, may have important implications for biotherapies such as vaccines and monoclonal antibodies.